top of page
Advancing Antibody Therapeutics
Large Molecules to Small Solutions with Bioconversion Innovation
Bifrost Medicines
Pioneering a new era in patient-centered therapeutics through the power of small molecule bioconversion
By transforming complex, large-molecule drugs into small-molecule treatments, we are creating medicines that are more accessible, cost-effective, and optimized for better patient outcomes.
Our Pipeline
Our pipeline is focused on developing first-in-class, small molecule drugs targeting key areas with high patient needs.
Target | Example Market Therapeutic | Annual Sales (USD) | Bifrost Status |
|---|---|---|---|
α4β1 | Tysarbi | $2.03B | In Development |
CD38 | Daratumumab | $10B | In Development |
CD20 | Rituxan | $6.5B | In Development |
PD-1 | Keytruda | $25B | In Evaluation |
GLP-1 | Ozempic, Wegovy | > $33B | Pending Design |
bottom of page